Jazz Pharmaceuticals plc Capital Expenditures
Jazz Pharmaceuticals plc (JAZZ) reported Capital Expenditures of $37.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-03
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $18.10M, a 40.31% increase year-over-year.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $19.70M, a 41.73% increase year-over-year.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $16.73M, a 25.91% increase year-over-year.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $15.22M, a 41.11% increase year-over-year.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for fiscal 2025 was $58.75M, a 54.33% increase from fiscal 2024.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for fiscal 2024 was $38.07M, a 58.88% increase from fiscal 2023.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for fiscal 2023 was $23.96M, a 17.50% decline from fiscal 2022.
- Jazz Pharmaceuticals plc payments to acquire property, plant, and equipment for fiscal 2022 was $29.05M, a 5.08% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $37.80M 10-Q · filed 2026-08-03 | $54.53M derived: sum of 3 quarters · filed 2026-08-03 | $69.75M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $19.70M 10-Q · filed 2026-05-05 | $36.43M derived: sum of 2 quarters · filed 2026-05-05 | $51.65M derived: sum of 3 quarters · filed 2026-05-05 | $64.55M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $16.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $31.95M derived: sum of 2 quarters · filed 2026-02-24 | $44.85M derived: sum of 3 quarters · filed 2026-08-03 | $58.75M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $15.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $28.12M derived: sum of 2 quarters · filed 2026-08-03 | $42.02M 10-Q · filed 2025-11-05 | $55.31M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $26.80M 10-Q · filed 2026-08-03 | $26.85M 10-Q · filed 2025-08-06 | $40.09M derived: sum of 3 quarters · filed 2026-08-03 | $50.88M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $13.90M 10-Q · filed 2026-05-05 | $13.88M 10-Q · filed 2025-05-07 | $27.19M derived: sum of 2 quarters · filed 2026-05-05 | $37.98M derived: sum of 3 quarters · filed 2026-05-05 | $45.07M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.07M derived: sum of 2 quarters · filed 2026-02-24 | $31.17M derived: sum of 3 quarters · filed 2026-02-24 | $38.07M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $10.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $17.88M derived: sum of 2 quarters · filed 2025-11-05 | $24.78M 10-Q · filed 2025-11-05 | $34.88M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $7.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $13.99M 10-Q · filed 2025-08-06 | $24.10M derived: sum of 3 quarters · filed 2026-02-24 | $28.40M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $6.90M 10-Q · filed 2025-05-07 | $17.01M derived: sum of 2 quarters · filed 2026-02-24 | $21.30M derived: sum of 3 quarters · filed 2026-02-24 | $27.04M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.40M derived: sum of 2 quarters · filed 2026-02-24 | $20.14M derived: sum of 3 quarters · filed 2026-02-24 | $23.96M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $10.04M derived: sum of 2 quarters · filed 2024-11-07 | $13.86M 10-Q · filed 2024-11-07 | $23.24M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $9.56M 10-Q · filed 2024-08-01 | $18.94M derived: sum of 3 quarters · filed 2025-02-26 | $14.04M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $3.82M 10-Q · filed 2024-05-02 | $13.20M derived: sum of 2 quarters · filed 2025-02-26 | $8.30M derived: sum of 3 quarters · filed 2025-02-26 | $20.58M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $4.48M derived: sum of 2 quarters · filed 2025-02-26 | $16.75M derived: sum of 3 quarters · filed 2025-02-26 | $29.05M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | -$4.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $7.38M derived: sum of 2 quarters · filed 2023-11-08 | $19.67M 10-Q · filed 2023-11-08 | $29.64M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $12.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $24.57M 10-Q · filed 2023-08-09 | $34.54M derived: sum of 3 quarters · filed 2024-02-28 | $42.87M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $12.29M 10-Q · filed 2023-05-10 | $22.26M derived: sum of 2 quarters · filed 2024-02-28 | $30.59M derived: sum of 3 quarters · filed 2024-02-28 | $37.77M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $9.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $18.30M derived: sum of 2 quarters · filed 2024-02-28 | $25.47M derived: sum of 3 quarters · filed 2024-02-28 | $27.64M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $8.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $15.51M derived: sum of 2 quarters · filed 2022-11-09 | $17.67M 10-Q · filed 2022-11-09 | $21.79M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $9.35M 10-Q · filed 2022-08-03 | $13.46M derived: sum of 3 quarters · filed 2023-03-01 | $16.83M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $2.17M 10-Q · filed 2022-05-04 | $6.28M derived: sum of 2 quarters · filed 2023-03-01 | $9.65M derived: sum of 3 quarters · filed 2023-03-01 | $12.34M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $7.48M derived: sum of 2 quarters · filed 2023-03-01 | $10.17M derived: sum of 3 quarters · filed 2023-03-01 | $15.00M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.06M derived: sum of 2 quarters · filed 2021-11-09 | $10.89M 10-Q · filed 2021-11-09 | $18.03M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $7.52M 10-Q · filed 2021-08-03 | $14.66M derived: sum of 3 quarters · filed 2022-03-01 | $25.74M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $4.83M 10-Q · filed 2021-05-04 | $11.97M derived: sum of 2 quarters · filed 2022-03-01 | $23.05M derived: sum of 3 quarters · filed 2022-03-01 | $37.02M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $18.22M derived: sum of 2 quarters · filed 2022-03-01 | $32.19M derived: sum of 3 quarters · filed 2022-03-01 | $40.13M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $11.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $25.05M derived: sum of 2 quarters · filed 2020-11-02 | $33.00M 10-Q · filed 2020-11-02 | |||
| 2019-06-30 | $13.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $21.91M 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | $7.95M 10-Q · filed 2020-05-05 | |||||
| 2018-12-31 | $20.37M 10-K · filed 2021-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |